List of Excipients in Branded Drug YARGESA

Generic Drugs Containing YARGESA

Company	Ingredient	NDC	Excipient
Edenbridge Pharmaceuticals LLC	miglustat	42799-709	FERROSOFERRIC OXIDE
Edenbridge Pharmaceuticals LLC	miglustat	42799-709	GELATIN
Edenbridge Pharmaceuticals LLC	miglustat	42799-709	MAGNESIUM STEARATE
Edenbridge Pharmaceuticals LLC	miglustat	42799-709	POVIDONE
Edenbridge Pharmaceuticals LLC	miglustat	42799-709	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in YARGESA?

# Of NDCs	Excipient
1	FERROSOFERRIC OXIDE
1	GELATIN
1	MAGNESIUM STEARATE
1	POVIDONE
1	PROPYLENE GLYCOL

YARGESA Excipient Strategy, Formulation Opportunities, Patent Exposure, and Commercial Outlook

Last updated: August 9, 2026

YARGESA is an oral miglustat product supplied as 100 mg hard capsules. Its commercial opportunity is driven less by active-ingredient exclusivity and more by differentiated excipients, tolerability, dose flexibility, pediatric usability, supply reliability, and market access. Miglustat’s core compound protection has expired in major markets, while formulation and process patents could still create narrower barriers if they claim clinically meaningful delivery or manufacturing advantages.

What is YARGESA and which active ingredient does it contain?

YARGESA contains miglustat, an orally administered iminosugar used in:

• Adult patients with mild-to-moderate type 1 Gaucher disease who are unsuitable for enzyme replacement therapy.
• Adult and adolescent patients with Niemann-Pick disease type C for treatment of progressive neurological manifestations.

Miglustat inhibits glucosylceramide synthase and intestinal disaccharidases. The drug is administered orally, typically in multiple daily doses, which increases the commercial importance of capsule tolerability and adherence.

Attribute	YARGESA profile
Active ingredient	Miglustat
Strength	100 mg hard capsule
Therapeutic class	Substrate reduction therapy
Primary indications	Type 1 Gaucher disease; Niemann-Pick disease type C
Route	Oral
Dosage form	Hard capsule
Molecular formula	C10H21NO4
Molecular weight	219.28 g/mol
Reference product	Zavesca
Regulatory category	Small-molecule pharmaceutical
Biosimilar exposure	None

The European Medicines Agency describes miglustat as a substrate reduction therapy and identifies gastrointestinal effects as a major tolerability issue associated with treatment (European Medicines Agency [EMA], 2018).

What excipients are used in YARGESA capsules?

Public product information for YARGESA identifies a conventional immediate-release hard-capsule platform. The formulation generally uses a filler or processing aid, a disintegrant, a lubricant, and capsule-shell materials. Exact excipient composition can vary by national product authorization and manufacturing site.

Typical excipient categories include:

Formulation function	Likely excipient strategy
Bulking and powder flow	Microcrystalline cellulose or comparable filler
Granule or blend processing	Povidone or another binder
Disintegration	Sodium starch glycolate or equivalent superdisintegrant
Lubrication	Magnesium stearate
Capsule shell	Gelatin or hypromellose
Opacity and color	Titanium dioxide and permitted iron oxides, where applicable

The key commercial point is that the current product is not dependent on a complex delivery system. That limits the technical barrier to entry but creates room for improvements directed at tolerability, dose administration, and manufacturing efficiency.

A regulatory dossier should distinguish the exact YARGESA composition from the excipient profile of Zavesca or other miglustat products. Substitution of capsule-shell materials, colorants, lubricants, or disintegrants can affect dissolution, stability, appearance, and bioequivalence.

Which excipient problems matter most for miglustat?

Gastrointestinal tolerability

Miglustat is associated with diarrhea, flatulence, abdominal discomfort, and weight loss. These effects arise primarily from intestinal enzyme inhibition and the pharmacology of the active ingredient, so excipients cannot eliminate the mechanism. They may, however, influence local dissolution, exposure rate, and gastrointestinal concentration.

Potential strategies include:

1. Slower dissolution to reduce the peak intestinal concentration.
2. Multiparticulate delivery to distribute the dose across the gastrointestinal tract.
3. Delayed-release or enteric-coated systems, subject to clinical and regulatory validation.
4. Co-packaged dietary-management materials that help patients manage carbohydrate-related gastrointestinal effects.

A conventional capsule that dissolves rapidly may be commercially inferior if a slower-release formulation reduces treatment discontinuation. The evidence burden is high because a modified-release version could alter efficacy and safety rather than merely improve handling.

Capsule swallowing and dose administration

Patients with Niemann-Pick disease type C can include adolescents and individuals with progressive neurological impairment. A smaller capsule, sprinkle formulation, oral suspension, or dispersible dosage form could address swallowing limitations.

The most practical opportunities are:

• 50 mg capsules for dose titration.
• A powder-filled capsule that can be opened and dispersed in a validated vehicle.
• An oral granule or sachet presentation.
• A low-volume oral suspension with improved dose measurement.
• A multiparticulate capsule that allows flexible dose adjustment.

Any administration method involving capsule opening must demonstrate dose uniformity, stability, compatibility with food or liquid, and acceptable pharmacokinetics.

Moisture and stability

Miglustat is a small, polar molecule with a formulation profile that may require attention to moisture uptake, capsule-shell brittleness, and powder flow. Commercially relevant excipient work includes:

• Low-moisture excipients.
• High-barrier blister packaging.
• Desiccant-supported bottles.
• Hypromellose capsules for vegetarian or moisture-sensitive products.
• Controlled lubricant levels to avoid dissolution retardation.
• Granulation processes that reduce segregation and fill-weight variability.

Packaging improvements may produce a lower regulatory burden than a new release mechanism. A more stable product could support distribution in humid markets and reduce manufacturing losses.

What formulations could be protected for YARGESA?

The strongest formulation opportunities are likely to involve a measurable clinical or manufacturing advantage rather than a simple excipient substitution.

Modified-release miglustat

A sustained-release product could reduce dosing frequency or moderate gastrointestinal exposure. The principal technical challenges are:

• Maintaining adequate systemic exposure.
• Preserving intestinal pharmacology where relevant.
• Avoiding reduced efficacy from excessive release delay.
• Establishing bioequivalence or conducting comparative clinical studies.
• Demonstrating that reduced dosing frequency improves adherence.

A once-daily or twice-daily product would have a stronger commercial proposition than a capsule with only cosmetic or manufacturing differences.

Pediatric and swallowing-friendly dosage forms

A pediatric formulation could use granules, a dispersible tablet, or an oral liquid. The formulation must address:

• Dose measurement accuracy.
• Palatability.
• Chemical and microbiological stability.
• Age-appropriate excipient safety.
• Food compatibility.
• Administration through feeding devices, if clinically relevant.

For orphan indications, the market is small. A formulation patent alone may not justify development unless it also creates reimbursement or procurement advantages.

Low-gastrointestinal-impact formulation

A formulation designed to reduce local intestinal exposure could provide a clinically meaningful product distinction. Candidate approaches include delayed dissolution, controlled release, or site-specific release. This area has the highest scientific risk because gastrointestinal effects are tied to miglustat’s mechanism and may not respond predictably to excipient changes.

Alternative capsule shells

Hypromellose capsules could support vegetarian positioning, improve supply flexibility, or reduce gelatin-related procurement restrictions. This is commercially useful in certain geographic markets but generally offers limited patent strength unless combined with a defined stability or dissolution advantage.

How strong is the YARGESA patent estate?

The core miglustat patent estate is commercially weak because the active ingredient has been marketed for many years and compound exclusivity has expired in major jurisdictions. The remaining opportunities are narrower and may include:

• Specific solid forms.
• Particle-size distributions.
• Capsule compositions.
• Modified-release systems.
• Manufacturing processes.
• Combination or co-administration methods.
• Disease-specific dosing regimens.
• Packaging and stability systems.

A formulation patent is more defensible when it claims a defined composition linked to a measurable result, such as dissolution behavior, impurity control, shelf life, or reduced variability. Broad claims covering “miglustat and a pharmaceutically acceptable excipient” would face substantial validity and obviousness risk.

Patent layer	Current commercial relevance
Miglustat compound	Low; historical exclusivity has expired
Basic immediate-release capsule	Low to moderate
Modified release	Moderate to high if clinically differentiated
Pediatric liquid or dispersible product	Moderate
Manufacturing process	Moderate where impurity or yield benefits are demonstrated
Packaging and stability	Moderate for emerging markets and supply continuity
Method of use	Variable; depends on jurisdiction and claim scope

No biosimilar pathway applies because miglustat is a chemically synthesized small molecule. Competitive entry is therefore based on generic-drug rules, not biologic interchangeability standards.

What is the Orange Book and FDA regulatory status of YARGESA?

YARGESA is not the reference product in the United States. The U.S. reference product is Zavesca, which contains miglustat. FDA approval of miglustat products is governed by the abbreviated new drug application pathway where the generic applicant can establish pharmaceutical equivalence and bioequivalence.

The FDA Orange Book is relevant to Zavesca and approved U.S. generic miglustat products, not automatically to the YARGESA brand sold outside the United States. Orange Book-listed patents, pediatric exclusivity, and regulatory exclusivity must be reviewed by product and application number. The absence of an Orange Book listing for a specific YARGESA product does not determine patent status in Europe, Canada, the United Kingdom, or other jurisdictions (U.S. Food and Drug Administration [FDA], 2024).

When did miglustat lose exclusivity?

Miglustat has been commercially available since the early 2000s. Its original market protection and orphan exclusivity periods have expired in the major jurisdictions where Zavesca was first approved.

Event	Approximate timing
European authorization of Zavesca	2002
U.S. approval of Zavesca	2003
U.S. orphan exclusivity period	Expired after the statutory orphan period
Core compound protection	Expired in major markets
Generic-entry period	Open, subject to local formulation and regulatory requirements
YARGESA commercial opportunity	Primarily price, supply, formulation, and market access

The relevant commercial barrier is no longer basic compound exclusivity. It is the ability to obtain approval, demonstrate bioequivalence, manage manufacturing cost, and secure reimbursement in a small orphan-disease market.

Are there Paragraph IV challenges or patent litigation risks?

Paragraph IV risk depends on the specific U.S. generic application and the patents listed against the reference product. A generic applicant may certify that listed patents are invalid, unenforceable, or not infringed, but the commercial significance depends on whether any listed patent remains enforceable and relevant to the proposed product.

For YARGESA, the principal litigation risks are more likely to arise from:

• A newly patented modified-release formulation.
• A pediatric dosage form.
• A manufacturing process patent.
• A formulation using a defined excipient ratio.
• A dosing regimen or method-of-use patent.
• Trade-secret claims involving manufacturing or analytical controls.

An immediate-release miglustat capsule based on conventional excipients is generally more exposed to ordinary generic competition than to a durable patent barrier. A Paragraph IV strategy would have greater value against a narrow secondary patent than against the expired compound estate.

Which companies could challenge YARGESA commercially?

Competition can come from several groups:

1. Generic manufacturers supplying miglustat capsules.
2. Regional pharmaceutical companies holding national marketing authorizations.
3. Specialty pharmaceutical companies developing improved orphan-disease formulations.
4. Contract manufacturers offering lower-cost capsule production.
5. Companies seeking public tenders in Europe and emerging markets.

The most credible competitive products will combine regulatory approval with reliable supply. In a small market, a low-cost manufacturer with limited formulation differentiation can still pressure price if it has strong distribution and reimbursement access.

What licensing deals could create value around YARGESA?

Licensing opportunities are most credible in four areas:

Formulation licensing

A controlled-release, pediatric, or dispersible miglustat formulation could be licensed to a specialty company with orphan-disease distribution. The deal would require clinical data sufficient to support the claimed benefit.

Regional commercialization

YARGESA rights can be licensed by territory where the originator, generic sponsor, or specialty distributor lacks local infrastructure. Attractive territories include markets with established rare-disease reimbursement and limited generic competition.

Manufacturing partnerships

A capsule manufacturer with high-containment, low-moisture, or flexible-dose capabilities could supply YARGESA under a contract manufacturing or co-development agreement.

Combination support products

Dietary-management products, patient-support programs, and adherence services may be commercialized alongside miglustat, although they are not substitutes for a protected pharmaceutical formulation.

What is the revenue exposure and market size?

Miglustat addresses rare diseases, so unit volume is limited relative to mass-market medicines. Revenue depends heavily on:

• Patient identification and diagnosis.
• Reimbursement for orphan medicines.
• Annual treatment duration.
• Geographic price controls.
• Generic substitution.
• Availability of enzyme replacement therapy alternatives in Gaucher disease.
• Treatment persistence despite gastrointestinal adverse events.

The main revenue risk is price erosion after generic entry. The main upside is a differentiated product that improves adherence or expands use among patients who cannot tolerate or administer conventional capsules.

A 50 mg strength or patient-friendly dosage form could increase revenue per treated patient only if payers recognize the clinical value. Otherwise, it may shift existing volume rather than expand the market.

How does YARGESA compare with competing treatments?

Product category	Main advantage	Main limitation
YARGESA or other miglustat capsules	Oral administration; no infusion	Gastrointestinal adverse effects; multiple daily dosing
Enzyme replacement therapy for Gaucher disease	Established efficacy; disease-specific use	Intravenous administration and high treatment burden
Eliglustat	Oral substrate reduction option for selected Gaucher patients	Genotype, metabolism, and interaction restrictions
Other Niemann-Pick disease approaches	May target different disease mechanisms	Limited availability and disease-specific evidence

YARGESA’s strongest commercial position is oral treatment for patients who need an alternative to infusion therapy or who are unsuitable for enzyme replacement. Its weakest position is tolerability and the absence of a strong compound-level patent barrier.

Key Takeaways

• YARGESA is a 100 mg oral miglustat hard capsule.
• The active ingredient is an established small molecule with expired core exclusivity in major markets.
• Excipient opportunities center on gastrointestinal tolerability, dose flexibility, moisture stability, and swallowing-friendly administration.
• A 50 mg strength, dispersible product, oral liquid, or multiparticulate formulation could create commercial differentiation.
• Modified-release delivery offers the largest potential value but also the highest clinical and regulatory risk.
• Conventional immediate-release capsules face generic competition and have limited patent strength.
• No biosimilar pathway applies because miglustat is a synthetic small molecule.
• U.S. Orange Book and Paragraph IV analysis must be conducted against Zavesca and the relevant generic application, not solely against the YARGESA brand.
• Licensing value is strongest for validated formulation technology, regional distribution, and reliable low-cost manufacturing.

FAQs

Can YARGESA be reformulated without conducting a new clinical trial?

A formulation using different excipients may qualify for an abbreviated or bridging pathway if it demonstrates pharmaceutical equivalence, dissolution similarity, stability, and bioequivalence. Modified release, pediatric liquids, or products that change exposure may require additional clinical evidence.

Is a 50 mg miglustat capsule commercially attractive?

Yes, particularly for dose adjustment, renal impairment management, pediatric or adolescent use, and patients with gastrointestinal intolerance. Its commercial value depends on reimbursement and whether the strength reduces dose discontinuation.

Could an enteric-coated miglustat capsule reduce diarrhea?

It could alter the site and rate of drug release, but it may also reduce the pharmacological effect or change systemic exposure. A claim would require comparative clinical data rather than dissolution data alone.

What excipients should be avoided in a pediatric YARGESA formulation?

The formulation should avoid excipients with age-related safety concerns, excessive osmotic activity, poor palatability, and interactions with miglustat stability or absorption. The acceptable list depends on the target age range and jurisdiction.

Is a co-crystal or amorphous form of miglustat likely to create patent value?

Potentially, if the form provides improved stability, manufacturability, dissolution control, or bioavailability and is characterized by reproducible structural data. A purely theoretical solid-form claim would face significant validity risk.

References

1. European Medicines Agency. (2018). Yargesa: EPAR product information. EMA.

2. European Medicines Agency. (2002). Zavesca: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2003). Zavesca (miglustat) prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs. FDA.